Skip to main content
Log in

Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

In this work, heat stable dry powders of oxytocin (OT) suitable for delivery by oral inhalation were prepared. The OT dry powders were prepared by spray drying using excipients chosen to promote OT stability including trehalose, isoleucine, polyvinylpyrrolidone, citrate (sodium citrate and citric acid), and zinc salts (zinc chloride and zinc citrate). Characterization by laser diffraction indicated that the OT dry powders had a median particle size of 2 μm, making them suitable for delivery by inhalation. Aerodynamic performance upon discharge from proprietary dry powder inhalers was evaluated by Andersen cascade impaction (ACI) and in an anatomically correct airway (ACA) model, and confirmed that the powders had excellent aerodynamic performance, with respirable fractions up to 77% (ACI, 30 L/min). Physicochemical characterization demonstrated that the powders were amorphous (X-ray diffraction) with high glass transition temperature (modulated differential scanning calorimetry, MDSC), suggesting the potential for stabilization of the OT in a glassy amorphous matrix. OT assay and impurity profile were conducted by reverse phase HPLC and liquid chromatography-mass spectrometry (LC-MS) after storage up to 32 weeks at 40°C/75%RH. Analysis demonstrated that OT dry powders containing a mixture of citrate and zinc salts retained more than 90% of initial assay after 32 weeks storage and showed significant reduction in dimers and trisulfide formation (up to threefold reduction compared to control).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

OT:

Oxytocin

Tg:

Glass transition temperature

PVP:

Polyvinylpyrrolidone

MDSC:

Modulated differential scanning calorimetry

ACI:

Andersen cascade impactor

PIP:

Peak inspiratory pressure

ACA:

Anatomically correct airway

References

  1. Dept. of Reproductive Health and Research, WHO WHO recommendations for the prevention and treatment of postpartum hemorrhage; 2012.

  2. Guastella AJ, Hickie IB, McGuinness MM, et al. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology. 2013;38(5):612–25.

    Article  CAS  PubMed  Google Scholar 

  3. Hogerzeil HV, Walker GJA, de Goeje MJ. Stability of injectable oxytocics in tropical climates. WHOreportWHO/DAP/93.6;1993.

  4. Groot ANJA, Vree TB, Hogerzeil HV, Walker GJA. Stability of oral oxytocics in tropical climates: Results of simulation studies on oral ergometrine, oral ethylergometrine, buccal oxytocin and buccal desamino-oxytocin. Geneva: World Health Organization; 1997.

    Google Scholar 

  5. Prankerd RJ, Nguyen T-H, Ibrahim JP, et al. Pulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum hemorrhage in developing countries. PLoS ONE. 2013;8(12):e82965.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Hawe A, Poole R, Romeijn S, Kasper P, Jiskoot W. Towards heat-stable oxytocin formulations: analysis of degradation kinetics and identification of degradation products. Pharm Res. 2009;26(7):1679–88.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Avanti C, Amorij JP, Setyaningsih D, Hawe A. A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer. The AAPS Journal. 2011;13(2):284–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Patton J, Byron P. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67–74.

    Article  CAS  PubMed  Google Scholar 

  9. Depreter F, Pilcer G, Amighi K. Inhaled proteins: challenges and perspectives. Int J Pharm. 2013;447(1–2):251–80.

    Article  CAS  PubMed  Google Scholar 

  10. Manning MC, Chou D, Murphy B, Payne R, Katayama D. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–75.

    Article  PubMed  Google Scholar 

  11. Chang L, Pikal M. Mechanisms of protein stabilization in the solid state. J Pharm Sci. 2009;98:2886–908.

    Article  CAS  PubMed  Google Scholar 

  12. Carvalho T, Peters J, Williams R. Influence of particle size on regional lung deposition–what evidence is there? Int J Pharm. 2011;406(1–2):1–10.

    Article  CAS  PubMed  Google Scholar 

  13. Reinhard V. Pharmaceutical particle engineering via spray drying. Pharm Res. 2008;25(5):999–1022.

    Article  Google Scholar 

  14. Elversson J, Millqvist-Fureby A, Alderborn G, Elofsson U. Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying. J Pharm Sci. 2003;92:900–10.

    Article  CAS  PubMed  Google Scholar 

  15. Liao YH, Brown M, Nazir T, Quader A, Martin G. Effects of sucrose and trehalose on the preservation of the native structure of spray-dried lysozyme. Pharm Res. 2002;19(12):1847–53.

    Article  CAS  PubMed  Google Scholar 

  16. Mozziconacci O, Schöneich C. Photodegradation of oxytocin and thermal stability of photoproducts. J Pharm Sci. 2012;101(9):3331–46.

    Article  CAS  PubMed  Google Scholar 

  17. Avanti C, Permentier HP, van Dam A, et al. A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate. Mol Pharm. 2012;9(3):554–62.

    Article  CAS  PubMed  Google Scholar 

  18. Christina Avanti C, Hinrichs W, Casini A, et al. The formation of oxytocin dimers is suppressed by the zinc–aspartate–oxytocin complex. J Pharm Sci. 2013;102(6):1734–41.

    Article  PubMed  Google Scholar 

  19. Liu D, Seuthe AB, Ehrler OT, et al. Oxytocin-receptor binding: why divalent metals are essential. J Am Chem Soc. 2005;127(7):2024–5.

    Article  CAS  PubMed  Google Scholar 

  20. Wyttenbach T, Liu D, Bowers MT. Interactions of the hormone oxytocin with divalent metal ions. J Am Chem Soc. 2008;130(18):5993–6000.

    Article  CAS  PubMed  Google Scholar 

  21. Smutney C, Kinsey PS, Sahi C, Adamo B, Polidoro J, McLean S, et al. Dry powder inhaler and system for drug delivery, MannKind Corporation. USA Patent 8,636,001 B2.

  22. Adamo B, Shah S, Smutney C. Inhaler adaptor for a laser diffraction apparatus and method for measuring particle size distribution, MannKind Corporation. USA Patent 8,508,732 B2.

  23. Smutney C, Adamo B, Laurenzi B, Kinsey PS. Dry powder drug delivery system and methods, MannKind Corporation. USA Patent Appln. US2014/001106 A1.

  24. Adamo B, Polidoro J, Overfield D, Sahi C, Laurenzi B, Smutney C, Kinsey PS. Apparatus and method for simulating inhalation efforts, MannKind Corporation. USA Patent Appln. US 2012/0247235 A1.

  25. Lechuga-Ballesteros D, Charan C, Stults C, Stevenson C, Miller D, Vehring R, et al. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci. 2008;97(1):287–302.

    Article  CAS  PubMed  Google Scholar 

  26. Tarelli E, Corran PH, Bingham BR, Mollison H, Wait R. Lysine vasopressin undergoes rapid glycation in the presence of reducing sugars. J Pharm Biomed Anal. 1994;12(11):1355–61.

    Article  CAS  PubMed  Google Scholar 

  27. Wolfenden R, Yuan Y. Rates of spontaneous cleavage of glucose, fructose, sucrose, and trehalose in water, and the catalytic proficiencies of invertase and trehalas. J Am Chem Soc. 2008;130(24):7548–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Poole R, Kasper P, Jiskoot W. Formation of amide- and imide-linked degradation products between the peptide drug oxytocin and citrate in citrate-buffered formulations. J Pharm Sci. 2011;100:3018–22.

    Article  CAS  PubMed  Google Scholar 

  29. Yamashiro D, Hope D, du Vigneaud V. Isomeric dimers of oxytocin. J Am Chem Soc. 1968;90(14):3857–60.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karine Fabio.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 294 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fabio, K., Curley, K., Guarneri, J. et al. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation. AAPS PharmSciTech 16, 1299–1306 (2015). https://doi.org/10.1208/s12249-015-0314-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-015-0314-0

KEY WORDS

Navigation